J
Julie M. Vose
Researcher at University of Nebraska Medical Center
Publications - 569
Citations - 51589
Julie M. Vose is an academic researcher from University of Nebraska Medical Center. The author has contributed to research in topics: Transplantation & Lymphoma. The author has an hindex of 97, co-authored 541 publications receiving 46915 citations. Previous affiliations of Julie M. Vose include Memorial Hospital of South Bend.
Papers
More filters
Journal ArticleDOI
Phase I/II study incorporating intravenous hydroxyurea into high-dose chemotherapy for patients with primary refractory or relapsed and refractory intermediate-grade and high-grade malignant lymphoma.
TL;DR: Continuous IV HU appears to be less toxic and more effective than intermittent oral HU in this regimen, and the lower mortality and higher response rate with IV BCHE translated into a significantly superior probability of progression-free survival (PFS).
Journal ArticleDOI
Does Functional Imaging Distinguish Nodular Lymphocyte-Predominant Hodgkin Lymphoma From T-Cell/Histiocyte-Rich Large B-Cell Lymphoma?
Nicholas A. Barber,Fausto R. Loberiza,Anamarija M. Perry,Martin Bast,Karen P. Holdeman,Aliriza B. Esfahane,Dennis D. Weisenburger,Julie M. Vose,Philip J. Bierman,James O. Armitage,R. Gregory Bociek +10 more
TL;DR: Patients with NLPHL and an uncharacteristically higher SUVmax on PET/CT, or those with bone or extranodal involvement, should alert the clinician to consider the presence of THR-LBCL.
Journal ArticleDOI
DNMT3A mutations define a unique biological and prognostic subgroup associated with cytotoxic T-cells in PTCL-NOS.
Tyler A. Herek,Alyssa Bouska,Waseem Gul Lone,Sunandini Sharma,Catalina Amador,Tayla B Heavican-Foral,Yuping Li,Qi Wei,Dylan Jochum,Timothy C. Greiner,Lynnette Smith,Stefano Pileri,Andrew L. Feldman,Andreas Rosenwald,German Ott,Soon Thye Lim,Choon Kiat Ong,Joo Y. Song,Elaine S. Jaffe,Greg G. Wang,Louis M. Staudt,Lisa M. Rimsza,Julie M. Vose,Francesco D'Amore,Dennis D. Weisenburger,Wing C. Chan,Javeed Iqbal +26 more
TL;DR: Investigation of de novo DNA methyltransferase 3A mutations in common PTCL entities indicates that DNMT3A mutations define a cytotoxic subset in P TCL-TBX21 with prognostic significance, thus may further refine pathological heterogeneity in PTCl-NOS and suggest alternative treatment strategies for this subset.
Journal ArticleDOI
Treatment for non-Hodgkin's lymphoma in relapse. What are the alternatives?
TL;DR: Multiagent chemotherapy including anthracyclines can induce long-term disease-free survival in 40 to 45 percent of patients with intermediate-grade, aggressive non-Hodgkin's lymphoma.
Journal ArticleDOI
Comparison of Subcutaneous and Intravenous Administration of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor for Peripheral Blood Stem Cell Mobilization
Anne Kessinger,Michael R. Bishop,James R. Anderson,James O. Armitage,Philip J. Bierman,Elizabeth C. Reed,Stefano R. Tarantolo,Margaret A. Tempero,Julie M. Vose,Phyllis I. Warkentin +9 more
TL;DR: The mobilization effects of subcutaneous rhGM-CSF in these pretreated patients were similar to those of intravenous rh GMF, and no significant differences in the collected products or the time to hematopoietic recovery was found.